University of Michigan Comprehensive Cancer Center SC-2 — Ann Arbor, Michigan

University of Michigan Comprehensive Cancer Center SC-2 is a clinical research site located in Ann Arbor, Michigan, United States 48109.

Crixeo Clinical Trials Trust Score: 93/100 (GOOD). This profile has not yet been claimed by the site owner.

University of Michigan Comprehensive Cancer Center SC-2 has participated in 2 clinical trials.

Therapeutic areas: Cushing's Disease, Acromegaly, Neuroendocrine Tumors.

Sponsors: RECORDATI GROUP, Novartis Pharmaceuticals.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Ann Arbor

Browse all research sites in Michigan · View every site in Ann Arbor

Sponsor Feasibility Report

Trust Score: 93/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for University of Michigan Comprehensive Cancer Center SC-2?

University of Michigan Comprehensive Cancer Center SC-2 has a Crixeo Trust Score of 93/100 (GOOD). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has University of Michigan Comprehensive Cancer Center SC-2 conducted?

University of Michigan Comprehensive Cancer Center SC-2 has 2 clinical trials on record. Their work covers Cushing's Disease, Acromegaly, Neuroendocrine Tumors.

Is University of Michigan Comprehensive Cancer Center SC-2 accredited by Crixeo Clinical Trials?

University of Michigan Comprehensive Cancer Center SC-2 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about University of Michigan Comprehensive Cancer Center SC-2?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.